Considering the therapeutic importance of readily reaching the brain tumors and brain metastases commonly occurring in NSCLC, the interactions between repotrectinib and the ABC transporters in the BBB should be thoroughly investigated. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.